Erratum: Eular/ERA-EDTA recommendations for the management of ANCA-associated vasculitis (Annals of the Rheumatic Diseases (2016) 75 (1583-1594) DOI: 10.1136/annrheumdis-2016-209133);EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

Annals of the Rheumatic Diseases

Volumn 75, Issue 9, 2016, Pages 1583-1594

  Yates, M ^a,b   Watts, R A ^b,c   Bajema, I M ^d   Cid, M C ^e   Crestani, B ^f   Hauser, T ^g   Hellmich, B ^h   Holle, J U ⁱ   Laudien, M ^j   Little, M A ^k   Luqmani, R A ^l   Mahr, A ^m   Merkel, P A ⁿ   Mills, J ^o   Mooney, J ^a   Segelmark, M ^p   Tesar, V ^q   Westman, K ^r   Vaglio, A ^s   Yalçındağ, Nilüfer ^t   Jayne, D R ^u   Mukhtyar, C ^a   more..

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF BARCELONA   (Spain)

^f BICHAT HOSPITAL   (France)

^g Gruppenpraxis Immunologie Zentrum   (Switzerland)

^h Kreiskliniken Esslingen   (Germany)

ⁱ Schleswig Holstein Mitte   (Germany)

^j UNIVERSITY OF KIEL   (Germany)

^k ADELAIDE AND MEATH HOSPITAL   (Ireland)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o West Bank House   (United Kingdom)

^p LINKÖPING UNIVERSITY   (Sweden)

^q CHARLES UNIVERSITY   (Czech Republic)

^r LUND UNIVERSITY   (Sweden)

^s UNIVERSITY HOSPITAL OF PARMA   (Italy)

^t ANKARA UNIVERSITY   (Turkey)

^u ADDENBROOKE S HOSPITAL   (United Kingdom)

more..

Author keywords

Corticosteroids; Cyclophosphamide; Disease Activity; Systemic vasculitis; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT;

ANCA ASSOCIATED VASCULITIS; CARDIOVASCULAR RISK; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MANAGED CARE; MEDICAL DECISION MAKING; PATIENT CARE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BIOPSY; DISEASE MANAGEMENT; PATHOLOGY; PLASMA EXCHANGE; PROCEDURES; RECURRENT DISEASE; REMISSION; RETREATMENT; STANDARDS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BIOPSY; DISEASE MANAGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMA EXCHANGE; RECURRENCE; REMISSION INDUCTION; RETREATMENT;

EID: 84978946297     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209133corr1     Document Type: Erratum

References (151)

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
2. Watts RA, Al-Taiar A, Scott DG, et al. Prevalence and incidence of Wegener's granulomatosis in the UK general practice research database. Arthritis Rheum 2009;61:1412-16.
3. Mohammad AJ, Jacobsson LT, Westman KW, et al. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 2009;48:1560-5.
4. Takala JH, Kautiainen H, Malmberg H, et al. Incidence of Wegener's granulomatosis in Finland 1981-2000. Clin Exp Rheumatol 2008;26(3 Suppl 49): S81-85.
5. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, et al. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005;53:93-9.
6. Gibelin A, Maldini C, Mahr A. Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement. Semin Respir Crit Care Med 2011;32:264-73.
7. Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004;51:92-9.
8. Ormerod AS, Cook MC. Epidemiology of primary systemic vasculitis in The Australian Capital Territory and south-eastern New South Wales. Intern Med J 2008;38:816-23.
9. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67:1004-10.
10. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-7.
11. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
12. Boomsma MM, Bijl M, Stegeman CA, et al. Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. Arthritis Rheum 2002;47:196-201.
13. Koutantji M, Harrold E, Lane SE, et al. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum 2003;49:826-37.
14. Anderson K, Klassen J, Stewart SA, et al. Does geographic location affect incidence of ANCA-associated renal vasculitis in northern Saskatchewan, Canada? Rheumatology 2013;52:1840-4.
15. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients. Arthritis Rheumi 1999;42:421-30.
16. Carruthers DM, Watts RA, Symmons DPM, et al. Wegener's granulomatosis-increased incidence or increased recognition? Br J Rheumatol 1996;35:142-5.
17. Hoffman GS, Thomas-Golbanov CK, Chan J, et al. Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 2003;30:1017-21.
18. Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum 1996;39:1754-60.
19. Elmedhem A, Adu D, Savage COS. Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 2003;18:1001-4.
20. Rahmattulla C, de Lind van Wijngaarden RA, Berden AE, et al. Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. Rheumatology (Oxford) 2015;54:899-907.
21. Homma S, Suzuki A, Sato K. Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist. Clin Exp Nephrol 2013;17: 667-71.
22. Le Berre L, Dufay A, Cantarovich D, et al. Early and irreversible recurrence MPO-ANCA-positive glomerulonephritis after renal transplantation. Clin Nephrol 2015;83:357-62.
23. Schokkenbroek AA, Franssen CF, Dikkers FG. Dilatation tracheoscopy for laryngeal and tracheal stenosis in patients with Wegener's granulomatosis. Eur Arch Otorhinolaryngol 2008;265:549-55.
24. Venhoff N, Effelsberg NM, Salzer U, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS ONE 2012;7:e37626.
25. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
26. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32.
27. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94.
28. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84.
29. Knight A, Askling J, Granath F, et al. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004;63:1307-11.
30. Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013;72:1011-17.
31. Aasarad K, Bostad L, Hammerstram J, et al. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. Nephrol Dial Transplant 2001;16:953-60.
32. Schnabel A, Holl-Ulrich K, Dalhoff K, et al.Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J 1997;10:2738-43.
33. Jennings CR, Jones NS, Dugar J, et al. Wegener's granulomatosis-a review of diagnosis and treatment in 53 subjects. Rhinology 1998;36:188-91.
34. Devaney KO, Travis WD, Hoffman G, et al. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990;14:555-64.
35. Travis WD, Hoffman GS, Leavitt RY, et al. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 1991;15:315-33.
36. Prasad N, Kumar S, Manjunath R, et al. Real-time ultrasound-guided percutaneous renal biopsy with needle guide by nephrologists decreases post-biopsy complications. Clin Kidney J 2015;8:151-6.
37. Basic-Jukic N, Kes P, Glavas-Boras S, et al. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 2005;9:391-5.
38. Corapi KM, Chen JL, Balk EM, et al. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis 2012;60:62-73.
39. Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010;21:1628-36.
40. Chang DY, Wu LH, Liu G, et al. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant 2012;27:2343-9.
41. Noone DG, Twilt M, Hayes WN, et al. The new histopathologic classification of ANCA-associated GN and its association with renal outcomes in childhood. Clin J Am Soc Nephrol 2014;9:1684-91.
42. Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener's Granulomatosis. N Engl J Med 1971;284:938-42.
43. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
44. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997;90:401-9.
45. Haubitz M, Frei U, Rother U, et al. Cyclophosphamide pulse therapy in Wegener's granulomatosis. Nephrol Dial Transplant 1991;6:531-4.
46. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98. doi: 10.1002/1529-0131(199712) 40:12<2187::AID-ART12>3.0.CO;2-H
47. De Groot K, Adu D, Savage COS. The value of pulse cyclophosphamide in ANCA-associated vasculitis: Meta-analysis and critical review. Nephrol Dial Transplant 2001;16:2018-27.
48. Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012;71:955-60.
49. Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007;57:686-93.
50. Stillwell TJ, Benson RC Jr, DeRemee RA, et al. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988;31:465-70.
51. Hellmich B, Kausch I, Doehn C, et al. Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide?. Ann Rheum Dis 2004;63:1183-5.
52. Chakravarty K, McDonald H, Pullar T, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2008;47:924-5.
53. Chung JB, Armstrong K, Schwartz JS, et al. Cost-effectiveness of prophylaxis against pneumocystis carinii pneumonia in patients with Wegener's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 2000;43:1841-8.
54. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: A major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995;151(3 Pt I):795-9.
55. Jarrousse B, Guillevin L, Bindi P, et al. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 1993;11:615-21.
56. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
57. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
58. Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 2016;75:396-401.
59. Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403-9.
60. Mersereau J, Dooley MA. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Rheum Dis Clin North Am 2010;36:99-108, viii.
61. Silva CA, Hallak J, Pasqualotto FF, et al. Gonadal function in Male adolescents and young males with juvenile onset systemic lupus erythematosus. JRheumatol 2002;29:2000-5.
62. Schrader M, Heicappell R, Muller M, et al. Impact of chemotherapy on Male fertility. Onkologie 2001;24:326-30.
63. Clowse ME, Copland SC, Hsieh TC, et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2011;63:1777-81.
64. Stassen PM, Tervaert JWC, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007;66:798-802.
65. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
66. Mansfield N, Hamour S, Habib AM, et al. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant 2011;26:3280-6.
67. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
68. Jayne DRW, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8.
69. Sokotowska B, Szczeklik W, Mastalerz L, et al. Effect of delayed diagnosis on disease course and management of Churg-Strauss syndrome: a retrospective study. Clin Rheumatol 2013;32:349-54.
70. Takala JH, Kautiainen H, Malmberg H, et al. Wegener's granulomatosis in Finland in 1981-2000: clinical presentation and diagnostic delay. Scand J Rheumatol 2008;37:435-8.
71. Howse M, Main J. Simple urine testing could avoid delay in the diagnosis of rapidly progressive glomerulonephritis. Postgrad Med J 1997;73:808-9.
72. Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542-8.
73. Holle JU, Voigt C, Both M, et al. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford) 2013;52:875-82.
74. Hoffman GS, Leavitt RY, Kerr GS, et al. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992;35:1322-9.
75. Sneller MC, Hoffman GS, Talar-Williams C, et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995;38:608-13.
76. Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999;26:1134-9.
77. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000;43:1836-40.
78. Stone JH. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
79. De Groot K, Muhler M, Reinhold-Keller E, et al. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998;25:492-5.
80. Metzler C, Hellmich B, Gause A, et al. Churg Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004;22(6 SUPPL.):S-52-61.
81. Metzler C, Hellmich B, Gause A, et al. Churg Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004;22(Suppl 36):S52-61.
82. Faurschou M, Westman K, Rasmussen N, et al. Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:3472-7.
83. Hu W, Liu C, Xie H, et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008;23:1307-12.
84. Han F, Liu G, Zhang X, et al. Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am JNephrol 2011;33:185-92.
85. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis Rheum 2010;62:9-21.
86. Miloslavsky EM, Specks U, Merkel PA, eta/. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol 2015;67:1629-36.
87. Klemmer PJ, Chalermskulrat W, Reif MS, et a/. Plasmapheresis Therapy for Diffuse Alveolar Hemorrhage in Patients with Small-Vessel Vasculitis. Am J Kidney Dis 2003;42:1149-53.
88. Levy JB, Turner AN, Rees AJ, et a/. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001;134:1033-42.
89. Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004;66:1535-40.
90. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013;14:73.
91. Walsh M, Casian A, Flossmann O, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013;84:397-402.
92. Walsh M, Catapano F, Szpirt W, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am JKidneyDis 2011;57:566-74.
93. Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis-a clinical randomized controlled trial. Nephrol Dial Transplant 2011;26:206-13.
94. Peters DK, Rees AJ, Lockwood CM, et al. Treatment and prognosis in antibasement membrane antibody-mediated nephritis. Transp ant Proc 1982;14:513-21.
95. Slot MC, Tervaert JWC, Boomsma MM, et al. Positive Classic Antineutrophil Cytoplasmic Antibody (C-ANCA) Titer at Switch to Azathioprine Therapy Associated with Relapse in Proteinase 3-Related Vasculitis. Arthritis Rheum 2004;51:269-73.
96. Langford CA, Talar-Williams C, Barron KS, et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-9.
97. Reinhold-Keller E, Fink COE, Herlyn K, et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002;47:326-32.
98. Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007;46:1087-91.
99. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371:1771-80.
100. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010;304:2381-8.
101. Stegeman CA, Tervaert JWC, De Jong PE, et al. Trimethoprim-sulfamethoxazole (Co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996;335:16-20.
102. Reinhold-Keller E, De Groot K, Rudert H, et al. Response to trimethoprim/ sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996;89:15-23.
103. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-17.
104. Springer J, Nutter B, Langford CA, et al. Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore) 2014;93:82-90.
105. Pagnoux C, Carette S, Khalidi NA, et al. Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 2015;33(2 Suppl 89):77-83.
106. Walsh M, Merkel PA, Mahr A, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken) 2010;62:1166-73.
107. Mohammad AJ, Segelmark M. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol 2014;41:1366-73.
108. Berden AE, Jones RB, Erasmus DD, et al. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 2012;23:313-21.
109. Ford SL, Polkinghorne KR, Longano A, et al. Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis. Am J Kidney Dis 2014;63:227-35.
110. Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008;58:2908-18.
111. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
112. Pullerits R, Ljevak M, Vikgren J, et al. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. Scand J Immunol 2012;76:411-20.
113. Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephro Dia Transp ant 2011;26:2865-71.
114. Seror R, Pagnoux C, Ruivard M, et al. Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis 2010;69:2125-30.
115. Miloslavsky EM, Specks U, Merkel PA, et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2013;65:2441-9.
116. Muso E, Ito-Ihara T, Ono T, et al. Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis 2004;57:S17-18.
117. Jayne DRW, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000;93:433-9.
118. Fortin PM, Tejani AM, Bassett K, et al. Intravenous immunoglobulin as adjuvant therapy for Wegener'sgranulomatosis.Cochrane Database Syst Rev 2013;1:CD007057.
119. Tomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatology (Oxford) 2012;51:100-9.
120. Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007;147:611-19.
121. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025-33.
122. Birck R, Schmitt WH, Kaelsch IA, et al. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: Systematic review. Am J Kidney Dis 2006;47:15-23.
123. Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999;111:507-13.
124. Savige J, Dimech W, Fritzler M, et al. Addendum to the International Consensus Statement on testing and reporting of Antineutrophil Cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2003;120:312-18.
125. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener'sgranulomatosis. Am J Med 2007;120:643.e9-14.
126. Stone JH. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003;48:2299-309.
127. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827-32.
128. Suppiah R, Mukhtyar C, Flossmann O, et al. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford) 2011;50:899-905.
129. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
130. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.
131. de Groot K, Gross WL, Herlyn K, et al. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001;55:31-8.
132. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17-28.
133. Merkel PA, Cuthbertson DD, Hellmich B, et al. Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis 2009;68:103-6.
134. Robson J, Doll H, Suppiah R, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 2015;74:177-84.
135. Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 2015;54:1153-60.
136. Stassen PM, Sanders JS, Kallenberg CG, et al.Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2008;23:654-8.
137. Jeffs LS, Peh CA, Jose MD, et al. Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton) 2015;20:343-51.
138. Holvast A, Stegeman CA, Benne CA, et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2009;68:873-8.
139. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis.2011;70:414-22.
140. Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011;63:588-96.
141. Herlyn K, Gross WL, Reinhold-Keller E. [Longitudinal effects of structured patient education programs for vasculitis patients]. Z Rheumatol 2008;67: 206-10.
142. Mooney J, Spalding N, Poland F, et al. The informational needs of patients with ANCA-associated vasculitis-development of an informational needs questionnaire. Rheumatology (Oxford) 2014;53:1414-21.
143. Herlyn K, Hellmich B, Seo P, et al. Patient-reported outcome assessment in vasculitis May provide important data and a unique perspective. Arthritis Care Res (Hoboken) 2010;62:1639-45.
144. Langford CA. Update on Wegener granulomatosis. Cleve Clin J Med 2005;72:689-90, 693-7.
145. Seo P, Min YI, Holbrook JT, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78.
146. Basu N, Jones GT, Fluck N, et al. Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology (Oxford) 2010;49:1383-90.
147. Basu N, McClean A, Harper L, et al. Explaining fatigue in ANCA-associated vasculitis. Rheumatology (Oxford) 2013;52:1680-5.
148. Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036-43.
149. Basu N, McClean A, Harper L, et al. Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology (Oxford) 2014;53:953-6.
150. Walsh M, Mukhtyar C, Mahr A, et al. Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken) 2011;63:1055-61.
151. Basu N, McClean A, Harper L, et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis 2014;73:207-11.